logo
Plus   Neg
Share
Email

Moderna Says First Participant Dosed In Phase 1/2 Study Of COVID-19 Vaccine In Japan

Moderna Inc. (MRNA) said Thursday that the first participant has been dosed in the Phase 1/2 study of the company's vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co.

TAK-919 is Takeda's development code for Moderna's COVID-19 vaccine candidate.

According to the company, the placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.

Takeda plans to enroll 200 participants aged 20 years and above in Japan. Each participant will be assigned to receive a placebo or a 100 µg dose at both vaccinations. Participants will be followed through 12 months after the second vaccination, Moderna said. .

Previously, the companies said that Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate starting in the first half of 2021.

Moderna received authorization for its COVID-19 vaccine from regulatory authorities in the United States, Canada, Israel, the European Union, the United Kingdom and Switzerland. Additional authorizations are currently under review in other countries and by the World Health Organization.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate. Billionaire Warren Buffett's Berkshire Hathaway Inc. (BRK.A, BRK.B) reported that its fourth-quarter net earnings attributable to shareholders rose 23 percent to $35.84 billion from last year's $29.16 billion, with earnings per share improving to $23,015 per Class A share from $17,909 per Class A share in the prior year. Walmart Inc. has launched a nationwide drive to boost COVID-19 vaccination rates by reaching out to more residents in vulnerable communities. The retail giant will organize a series of community events at 43 locations in 18 states to administer the COVID-19 vaccine. Walmart said it plans to continue these new events over the next several weeks as vaccine allocations allow.
Follow RTT